Fresh analysis suggests that individuals who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional lifestyle regimens.
Published data in a major medical journal demonstrates that while overweight people often shed about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying such drugs should be informed of the potential of fast weight regain when the medication concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original weight in about 18 months.
Comparing Treatments
The analysis, which examined 37 of trials involving thousands of participants, compared the effects of the injectable medications with other pills.
Researchers note that individuals who lose weight through dieting generally see a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Experts suggest the mechanism of the jabs accounts for the accelerated rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
The NHS advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
People who have stopped the medication report a intense return of hunger.
"I experienced a trigger that goes on and you become extremely hungry," described a patient.
The struggle is worsened if individuals have not established lasting lifestyle or habit changes during treatment.
Significant Interest
Survey data show that millions of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective agents for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle management.
